Using intravenous lacosamide to treat acute pain in trigeminal neuralgia
Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study
This study is testing if intravenous lacosamide can help relieve severe facial pain in people with trigeminal neuralgia who come to the emergency room.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospital Universitari de Bellvitge Academic / other |
| Locations | 1 site (L'Hospitalet de Llobregat, Barcelona) |
| Trial ID | NCT06851910 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients with trigeminal neuralgia presenting to the emergency department. Conducted at Hospital Universitari de Bellvitge, the study will enroll approximately 20 patients over two years, assessing pain response using a Numerical Pain Rating Scale at various time points. The study aims to provide insights into the potential benefits of lacosamide for patients experiencing severe facial pain that is resistant to conventional therapies.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years diagnosed with classical or idiopathic trigeminal neuralgia experiencing acute pain exacerbations.
Not a fit: Patients with contraindications to lacosamide or those unable to provide informed consent due to mental illness or language barriers may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new option for patients suffering from acute pain exacerbations of trigeminal neuralgia.
How similar studies have performed: While evidence for intravenous treatments in acute trigeminal neuralgia is limited, previous studies have suggested potential benefits of similar approaches, making this investigation both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion. Inclusion Criteria: * Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3). * Age over 18 years. * Signed informed consent. Exclusion Criteria: * Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block). * Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent. * Language barrier. * Lack of cooperation.
Where this trial is running
L'Hospitalet de Llobregat, Barcelona
- Hospital de Bellvitge — L'Hospitalet de Llobregat, Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Albert Muñoz Vendrell, PhD — Hospital Universitari de Bellvitge
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.